Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10429-T4

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10429-T4-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

NP_001265355.2

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all LILRB4/CD85k/ILT3 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human LILRB4/CD85k/ILT3 protein
Human LILRB4/CD85k/ILT3
(Gly24-Glu259)
Accession # NP_001265355.2		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Gly24

Predicted Molecular Mass

53 kDa

SDS-PAGE

55-75 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human Apolipoprotein E3/ApoE3 (Catalog # 4144-AE) is immobilized at 5 μg/mL, 100 μL/well, the concentration of Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera (Catalog # 10429-T4) that produces 50% of the optimal binding response is approximately 0.8-5 μg/mL.

Reviewed Applications

Read 1 review rated 4 using 10429-T4 in the following applications:

Scientific Data Images for Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein, CF

Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein Binding Activity

Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein Binding Activity

When Recombinant Human Apolipoprotein E3 (Catalog # 4144-AE) is immobilized at 5 µg/mL, 100 µL/well, the concentration of Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera (Catalog #10429-T4) that produces 50% of the optimal binding response is approximately 0.8-5 µg/mL.
Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein SDS-PAGE

Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein SDS-PAGE

2 μg/lane of Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein (Catalog # 10429-T4) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 55-75 kDa and 110-150 kDa, respectively.

Formulation, Preparation and Storage

10429-T4
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: LILRB4/CD85k/ILT3

ILT3, also known as LILRB4, CD85k, and LIR5, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation (1). Mature human ILT3 consists of an extracellular domain (ECD) with two Ig-like domains, a transmembrane segment, and a cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM) (2). The mature ECD of human ILT3 shares 44% amino acid identity with mouse ILT3. Alternative splicing of human ILT3 generates an isoform that lacks the first ITIM and a secreted isoform that circulates in the serum of cancer patients (3, 4). ILT3 is expressed on dendritic cells (DC), monocytes, macrophages, and vascular endothelial cells (EC) (2, 5, 6). Ligation of ILT3 triggers ITIM-mediated inhibition of cell-activating signaling, leading to enhanced immune tolerance and reduced allogeneic graft rejection (2, 4, 7, 8). Soluble ILT3 induces the differentiation of CD8+ T suppressor cells (Ts) that can inhibit the effector functions of CD4+ Th cells and CD8+ CTL (4, 7, 9). In turn, CD8+ Ts cells induce ILT3 up-regulation and a tolerogenic phenotype in monocytes, DC, and EC (5, 6, 8, 10, 11). Recently, a novel anti-LILRB4 CAR-T Cell was been used to treat monocytic acute myeloid leukemia in humanized hematopoietic-reconstituted mice models (12).

References

  1. Vlad, G. et al. (2010) Int. Rev. Immunol. 29:119.
  2. Cella, M. et al. (1997) J. Exp. Med. 185:1743.
  3. Heinzmann, A. et al. (2000) Eur. J. Immunogenet. 27:121.
  4. Suciu-Foca, N. et al. (2007) J. Immunol. 178:7432.
  5. Gleissner, C.A. et al. (2007) Eur. J. Immunol. 37:177.
  6. Manavalan, J.S. et al. (2004) Int. Immunol. 16:1055.
  7. Vlad, G. and N. Suciu-Foca (2012) Exp. Mol. Pathol. 93:294.
  8. Chang, C.C. et al. (2002) Nat. Immunol. 3:237.
  9. Vlad, G. et al. (2006) Int. Immunopharmacol. 6:1889.
  10. Manavalan, J.S. et al. (2003) Transpl. Immunol. 11:245.
  11. Brenk, M. et al. (2009) J. Immunol. 183:145.
  12. John, S. et al. (2018) Mol. Ther. 26:2487.

Long Name

Leukocyte Immunoglobulin-like Receptor, Subfamily B (with TM and ITIM Domains), Member 4

Alternate Names

CD85k, HM18, ILT3, LIR5

Entrez Gene IDs

11006 (Human); 14728 (Mouse); 107128256 (Cynomolgus Monkey)

Gene Symbol

LILRB4

UniProt

NP_001265355.2

Additional LILRB4/CD85k/ILT3 Products

Product Documents for Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human LILRB4/CD85k/ILT3 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.